1Cowan KJ,Storey KB.Mitogen-activated protein kinases:new signaling pathways functioning in cellular responses to environmental stress[J].J Exp Biol,2003,206:107.
2Brose MS,Volpe,P,Feldman,M,et al.BRAF and RAS mutations in human lung cancer and melanoma[J].Cancer Res,2002,62:6997.
3Rajagopalan H,Bardelli A,Lengauer C,et al.Tumorigenesis:RAF/RAS oncogenes and mismatch-repair status[J].Nature,2002,418:934.
4Platanias LC.Map kinase signaling pathways and hematologic malignancies[J].Blood,2003,101:4667.
5Adeyinka A,Nui Y,Cherlet T,et al.Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression[J].Clin Cancer Res,2002,8:1747.
6Choi YJ,Fanidi A,White S,et al.The novel inhibitor BAY 43-9006 blocks signaling and proliferation in b-Raf mutant and wild type melanoma and colorectal tumor cell lines.Presented at Am Assoc Cancer Res 94th Annual Meeting[C].Washington,DC,2003:11.
7Wilhelm S,Carter C,Tang L,et al.BAY 43-9006 exhibits broad spectrum anti-tumor activity and targets Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].Cancer Res,2004,64:7099.
8Alai A,Hood JD,Frausto R,et al.Role of Raf in vascular protection from distinct apoptotic stimuli[J].Science,2004,301:7099.
9Strumberg D,Voliotis D,Moeller JG,et al.Results of phaseⅠpharmacokinetic and pharmacodynamic studies of Raf kinase inhibitor BAY 43-9006 in patients with solid tumors[J].Int J Clin Pharmacol Ther,2002,40:580.
10Ratain MJ,Elsen T,Stadler WM.Final findings from a phase Ⅱ,placebo-controlled,randomized discontinuation trial(RDT of sorafenib(BAY 43-9006) in patients with advanced renal carcinoma(RCC)[J].J Clin Oncol,2005,23:388.
同被引文献9
1Lin SL,Yan LY,Zhang XT. ER-alpha36,a variant of ER-alpha,promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways[J].PLoS One,2010,(02):e9013.
2左文述.现代乳腺肿瘤学[M]济南:山东科学技术出版社,2006133-137.
3Fiddes RJ,Janes PW,Sivertsen SP. Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells[J].Oncogene,1998,(21):2803-2813.doi:10.1038/sj.onc.1201815.
5Chen J,Katsifis A,Hu C. Insulin Decreases Therapeutic Efficacy in Colon Cancer Cell Line HT29 via the Activation of the PI3K/Akt Pathway[J].Curr Drug Discov Technol,2011,(02):119-125.doi:10.2174/157016311795563820.
6Ding S,Chamberlain M,McLaren A. Cross-talk between signalling pathways and the multidrug resistant protein MDR-1[J].British Journal of Cancer,2001,(08):1175-1184.doi:10.1054/bjoc.2001.2044.
7Jin W,Wu L,Liang K. Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells[J].British Journal of Cancer,2003,(01):185-191.doi:10.1038/sj.bjc.6601048.
